Edition:
United Kingdom

Natco Pharma Ltd (NATP.NS)

NATP.NS on National Stock Exchange of India

766.60INR
10:29am GMT
Change (% chg)

Rs-13.50 (-1.73%)
Prev Close
Rs780.10
Open
Rs777.90
Day's High
Rs780.90
Day's Low
Rs765.00
Volume
181,009
Avg. Vol
311,437
52-wk High
Rs1,090.00
52-wk Low
Rs671.10

Chart for

About

Natco Pharma Limited is a pharmaceutical company. The Company is engaged in developing, manufacturing and marketing finished dosage formulations (FDF) and active pharmaceutical ingredients (APIs). The Company's segments include active pharmaceuticals ingredient, finished dosage formulations, job works, pharmacy and others. The... (more)

Overall

Beta: 0.37
Market Cap(Mil.): Rs173,105.09
Shares Outstanding(Mil.): 174.31
Dividend: 1.25
Yield (%): 0.73

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.60
EPS (TTM): -- -- --
ROI: -- 14.90 10.66
ROE: -- 16.41 14.30

BRIEF-Natco Pharma Says Co's Mekaguda Facility Undergoing Routine U.S. FDA Inspection

* NATCO PHARMA CLARIFIES ON NEWS ITEM ON US FDA INSPECTION AT CO'S MEKAGUDA FACILITY IN TELANGANA

14 Feb 2018

BRIEF-India's Natco Pharma Dec-Qtr Consol Profit Rises

* DEC QUARTER CONSOL NET PROFIT 2.18 BILLION RUPEES VERSUS PROFIT 1.95 BILLION RUPEES YEAR AGO

06 Feb 2018

BRIEF-Natco Pharma Launches Tafnat, Tenofovir Alafenamide Tablets In India

* SAYS NATCO LAUNCHES TAFNAT, TENOFOVIR ALAFENAMIDE TABLETS, FOR TREATMENT OF CHRONIC HEPATITIS B, IN INDIA Source text for Eikon: Further company coverage:

18 Dec 2017

BRIEF-Natco Pharma Approved Allocation Of 10 Mln Shares At 915 Rupees/Share Upon Closure Of QIP

* NATCO PHARMA - APPROVED ALLOCATION OF 10 MILLION SHARES AT ISSUE PRICE OF 915 RUPEES PER SHARE UPON CLOSURE OF QIP Source text: http://bit.ly/2zbT0ZA Further company coverage:

14 Dec 2017

BRIEF-Natco Pharma Approves QIP Floor Price Of 937.63 Rupees/Shr

* SAYS APPROVED QIP FLOOR PRICE OF 937.63 RUPEES PER SHARE Source text: http://bit.ly/2AJA9El Further company coverage:

11 Dec 2017

BRIEF-India's Natco Pharma Sept-qtr consol profit up about 28 pct

* Sept quarter consol net profit 848 million rupees versus profit of 665 million rupees last year

02 Nov 2017

BRIEF-Natco Pharma's marketing partner Mylan launches generic glatiramer acetate in U.S.

* Says marketing partner mylan launches generic glatiramer acetate in U.S. Market Source text - http://bit.ly/2xUtxo0 Further company coverage:

05 Oct 2017

BRIEF-Natco Pharma gets shareholders' nod for re-appointing V.C. Nannapaneni as chairman, MD

* Gets shareholders' nod for re-appointment of V.C. Nannapaneni as chairman, MD Source text - http://bit.ly/2wuXVkS Further company coverage:

03 Oct 2017

BRIEF-Natco Pharma gets shareholders' nod for reappointment of V C Nannapaneni as chairman, MD

* Gets shareholders' nod for reappointment of V C Nannapaneni as chairman, MD

29 Sep 2017

Earnings vs. Estimates